Ilmay Bilge

Ilmay Bilge

Auto-generated profile, based on publicly available information

Ilmay Bilge

Pediatric Nephrology Department Koç University Faculty of Medicine Istanbul Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
CPChristian Patry
Christian Patry
NWNicholas J. A. Webb
Nicholas J. A. Webb
MFManuel Feisst
Manuel Feisst
KKKai Krupka
Kai Krupka
JBJan Becker
Jan Becker
BTBurkhard Tönshoff
Burkhard Tönshoff
Background: Complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are ultra-rare chronic kidney diseases with an overall poor prognosis, with approximately 40–50% of patients progressing to kidney failure within 10 years of diagnosis. C3G is characterized by a high rate of disease recurrence in the transplanted kidney. However, there is a lack of published data on clinical outcomes in the pediatric population following transplantation. Methods: In this multicenter longitudinal cohort study of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) registry, we compared the post-transplant outcomes of pediatric patients with C3G (n = 17) or IC-MPGN (n = 3) with a matched case–control group (n = 20). Results: Eleven of 20 children (55%) with C3G or IC-MPGN experienced a recurrence within 5 years post-transplant. Patients with C3G or IC-MPGN had a 5-year graft survival of 61.4%, which was significantly (P = 0.029) lower than the 5-year graft survival of 90% in controls; five patients with C3G or IC-MPGN lost their graft due to recurrence during this observation period. Both the 1-year (20%) and the 5-year (42%) rates of biopsy-proven acute rejection episodes were comparable between patients and controls. Complement-targeted therapy with eculizumab, either as prophylaxis or treatment, did not appear to be effective. Conclusions: These data in pediatric patients with C3G or IC-MPGN show a high risk of post-transplant disease recurrence (55%) and a significantly lower 5-year graft survival compared to matched controls with other primary kidney diseases. These data underscore the need for post-transplant patients for effective and specific therapies that target the underlying disease mechanism. Graphical

30 August 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
MTMehmet Taşdemir
Mehmet Taşdemir
NCNur Canpolat
Nur Canpolat
NYNurdan Yildiz
Nurdan Yildiz
GÖGül Özçelik
Gül Özçelik
MBMeryem Benzer
Meryem Benzer
IBIlmay Bilge
Ilmay Bilge
Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.

14 September 2021 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
SİSaid İncir
Said İncir
MTMehmet Taşdemir
Mehmet Taşdemir
BKBurak Kocak
Burak Kocak
BYBerna Yelken
Berna Yelken
EAEmre Arpali
Emre Arpali
ATAydin Turkmen
Aydin Turkmen

1 June 2021 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
BABagdagul Aksu
Bagdagul Aksu
ERErkin Rahimov
Erkin Rahimov
AYAlev Yilmaz
Alev Yilmaz
ZYZeynep Yuruk Yildirim
Zeynep Yuruk Yildirim
IBIlmay Bilge
Ilmay Bilge
ASAydan Sirin
Aydan Sirin

28 September 2020 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
BABagdagul Aksu
Bagdagul Aksu
ERErkin Rahimov
Erkin Rahimov
AYAlev Yilmaz
Alev Yilmaz
ZYZeynep Yuruk Yildirim
Zeynep Yuruk Yildirim
IBIlmay Bilge
Ilmay Bilge
ASAydan Sirin
Aydan Sirin

30 November 2025 in Pediatric Transplantation
Verified
Journal Article
Closed access
CPCemile Pehlivanoglu
Cemile Pehlivanoglu
FEFatih Erbey
Fatih Erbey
ÖÜÖzlem Ünlügedik
Özlem Ünlügedik
BABaşak Akyollu
Başak Akyollu
EYEbru Yılmaz
Ebru Yılmaz
IBIlmay Bilge
Ilmay Bilge